Download PDF
Thromb Haemost 2017; 117(02): 426-428
DOI: 10.1160/TH16-10-0496
Letters to the Editor
Schattauer GmbH

Fibrin clot strength measured by thrombelastography and outcomes after percutaneous coronary intervention

Rolf P. Kreutz
1   Krannert Institute of Cardiology, Indiana University School of Medicine, Indianapolis, Indiana, USA
,
Glen Schmeisser
1   Krannert Institute of Cardiology, Indiana University School of Medicine, Indianapolis, Indiana, USA
,
Benjamin Maatman
1   Krannert Institute of Cardiology, Indiana University School of Medicine, Indianapolis, Indiana, USA
,
Andrea Schaffter
1   Krannert Institute of Cardiology, Indiana University School of Medicine, Indianapolis, Indiana, USA
,
Anjan Sinha
1   Krannert Institute of Cardiology, Indiana University School of Medicine, Indianapolis, Indiana, USA
,
Elisabeth von der Lohe
1   Krannert Institute of Cardiology, Indiana University School of Medicine, Indianapolis, Indiana, USA
,
Jeffrey A. Breall
1   Krannert Institute of Cardiology, Indiana University School of Medicine, Indianapolis, Indiana, USA
› Author Affiliations Financial support: This study was supported in part, by the Indiana Clinical and Translational Sciences Institute funded, in part by Grant Number (U54-RR025761. Anantha Shekhar, PI) from the National Institutes of Health, National Center for Research Resources, Clinical and Translational Sciences Award, as well as the Indiana University Health Values Grant, the Indiana University Health – Indiana University School of Medicine Strategic Research Initiative, and internal funding from the Department of Medicine, Indiana University School of Medicine, Indianapolis. Sample processing and storage was performed in part by the Specimen Storage Facility (SSF) of the Indiana Clinical and Translational Sciences Institute (CTSI) which is supported, in part, by a Clinical and Translational Sciences Award (Grant # UL1TR001108. Anantha Shekhar, PI) and CTSI SSF facility construction was funded in part by grant CO6– RR020128–01. (R. S. Fife, PI, K. Cornetta, Co-I).
Further Information

Publication History

Received:01 July 2016

Accepted after minor revision:14 October 2016

Publication Date:
13 November 2017 (online)

Also available at
    Permissions and Reprints

Supplementary Material to this article is available online at www.thrombosis-online.com.

 

  • References

  • 1 Gurbel PA, Bliden KP, Guyer K. et al. Platelet reactivity in patients and recurrent events post-stenting: results of the PREPARE POST-STENTING Study. J Am Coll Cardiol 2005; 46: 1820-1826.
    CrossrefPubMedGoogle Scholar
  • 2 Bitar A, Kreutz RP. Role of Thrombelastography (TEG) in Risk Assessment and Guidance of Antithrombotic Therapy in Patients with Coronary Artery Disease. Drug Dev Res 2013; 74: 533-540.
    CrossrefPubMedGoogle Scholar
  • 3 Kreutz RP, Owens J, Lu D. et al. Platelet factor XIIIa release during platelet aggregation and plasma clot strength measured by thrombelastography in patients with coronary artery disease treated with clopidogrel. Platelets 2015; 26: 358-363.
    CrossrefPubMedGoogle Scholar
  • 4 Kreutz RP, Bitar A, Owens J. et al. Factor XIII Val34Leu polymorphism and recurrent myocardial infarction in patients with coronary artery disease. J Thromb Thrombolysis 2014; 38: 380-387.
    CrossrefPubMedGoogle Scholar
  • 5 Lu D, Owens J, Kreutz RP. Plasma and whole blood clot strength measured by thrombelastography in patients treated with clopidogrel during acute coronary syndromes. Thromb Res 2013; 132: e94-98.
    CrossrefPubMedGoogle Scholar
  • 6 Kreutz RP, Owens J, Breall JA. et al. C-reactive protein and fibrin clot strength measured by thrombelastography after coronary stenting. Blood Coagul Fibrinolysis 2013; 24: 321-326.
    CrossrefPubMedGoogle Scholar
  • 7 Thygesen K, Alpert JS, Jaffe AS. et al. Third universal definition of myocardial infarction. Circulation 2012; 126: 2020-2035.
    CrossrefPubMedGoogle Scholar
  • 8 Cutlip DE, Windecker S, Mehran R. et al. Academic Research Consortium. Clinical end points in coronary stent trials: a case for standardized definitions. Circulation 2007; 115: 2344-2351.
    CrossrefPubMedGoogle Scholar
  • 9 Mehran R, Rao SV, Bhatt DL. et al. Standardized bleeding definitions for cardiovascular clinical trials: a consensus report from the Bleeding Academic Research Consortium. Circulation 2011; 123: 2736-2747.
    CrossrefPubMedGoogle Scholar
  • 10 Ang L, Thani KB, Ilapakurti M. et al. Elevated plasma fibrinogen rather than residual platelet reactivity after clopidogrel pre-treatment is associated with an increased ischemic risk during elective percutaneous coronary intervention. J Am Coll Cardiol 2013; 61: 23-34.
    CrossrefPubMedGoogle Scholar
  • 11 Wiviott SD, Braunwald E, McCabe CH. et al. TRITON-TIMI 38 Investigators. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2007; 357: 2001-2015.
    CrossrefPubMedGoogle Scholar
  • 12 Wallentin L, Becker RC, Budaj A. et al. PLATO Investigators, Freij A, Thorsén M. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2009; 361: 1045-1057.
    CrossrefPubMedGoogle Scholar
  • 13 Bonaca MP, Bhatt DL, Cohen M. et al. PEGASUS-TIMI 54 Steering Committee and Investigators. Long-term use of ticagrelor in patients with prior myocardial infarction. N Engl J Med 2015; 372: 1791-1800.
    CrossrefPubMedGoogle Scholar
  • 14 Byrnes JR, Duval C, Wang Y. et al. Factor XIIIa-dependent retention of red blood cells in clots is mediated by fibrin a-chain crosslinking. Blood 2015; 126: 1940-1948.
    CrossrefPubMedGoogle Scholar
  • 15 Schlimp CJ, Solomon C, Ranucci M. et al. The effectiveness of different functional fibrinogen polymerization assays in eliminating platelet contribution to clot strength in thromboelastometry. Anesth Analg 2014; 118: 269-276.
    CrossrefPubMedGoogle Scholar